The National Institute of Diabetes and Digestive and Kidney Diseases has awarded Genalyte $500,000 to create a multiplexed assay for diagnosing and monitoring type 1 diabetes early. The assay will run on the company's Maverick Detection System, which automates the way multiple proteins found in one small test sample are identified and analyzed.
Men and women who became obese as children or teens had a higher risk of developing diabetes compared with those who became obese in adulthood, a study in Diabetes Care found. The results underscore the importance of addressing obesity at a young age to reduce the risk of diabetes onset, researchers said.
A newly developed antibody called mimAb1, which mimics the function of a naturally occurring molecule called fibroblast growth factor 21, helped induce weight loss and improve insulin sensitivity and BMI in obese monkeys, researchers reported in Science Translational Medicine. However, researchers said it is still unclear how the treatment would work in human patients.
Patients who received mobile-based diabetes care, including a wireless glucometer and a smartphone containing a personalized care plan, showed lower A1C levels at six months compared with those who had usual care, an analysis indicated. Researchers also found that patients on mobile-based care had better control of their bad cholesterol levels and were more likely to communicate online with their health care providers than those in the control group. The results appear in the Journal of the American Medical Informatics Association.
A total of 221 new drugs for diabetes and related diseases are awaiting FDA approval or are in clinical studies, according to a report from the Pharmaceutical Research and Manufacturers of America. The treatments include 130 for type 2 diabetes, 32 for type 1 diabetes, 14 for unspecified diabetes and 64 for related conditions, with some medications in multiple categories.